Medical Device News Magazine

Control 11F Mechanical Thrombectomy System Used Successfully to Remove a Large Clot

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

January 22, 2021

Control 11F Mechanical Thrombectomy System: Kishor Vora, M.D., FACC, FSCAI, CCDS, Medical Director at the Owensboro Heart & Vascular Clinic in Owensboro, Kentucky, USA removed the clots using FDA cleared Control 11F Mechanical Thrombectomy System.

“Control removed large blood clots in our first uses,” said Kishor Vora, M.D., FACC, FSCAI, CCDS, Medical Director at the Owensboro Heart & Vascular Clinic in Owensboro, Kentucky, USA. “Large venous blood clots in the legs is a serious condition. Patients may present with pain, swelling, and other symptoms. Left untreated, deep vein thrombosis (DVT) can lead to life-threatening pulmonary embolism. If clots are not removed from large veins like Common Femoral or Iliac veins in time, it can result in lifelong disabling symptoms like swelling in legs, pain, discoloration and non-healing ulcers.”

Blood-clot and embolic removal, or thrombectomy and embolectomy, is performed throughout the body. Coronary thrombectomy is performed in acute myocardial infarction (AMI), neurovascular thrombectomy in acute ischemic stroke, and peripheral thrombectomy is performed with peripheral arterial disease (PAD), chronic total occlusion (CTO), and deep vein thrombosis (DVT).

“The Control 11 French Mechanical Thrombectomy System can remove large clots,” said Shawn Fojtik, President of Control Medical Technology in Park City, Utah. “Patients, clinicians, and payors need more tools to remove diverse thrombus without excessive expense and complex capital equipment. A disposable $2,000 – $15,000+ device per-patient technology is not the only way to remove blood clots, especially if it sucks too much blood.”

During thrombectomy & embolectomy procedures, clinicians typically track a catheter to the thrombus/emboli and then use a basic syringe or high-performance aspirator/electric pump to pull the clot/emboli out. Basic syringes lack speed, force, volume, and control. Electric pumps improve force but are complex and reported to suck too much blood with 7+ French (~2.25mm+) outer diameter catheters.

“Reducing blood loss is important when removing large clot & emboli,” continued Mr. Fojtik. “Large catheters can remove blood too fast when using electric pumps. Our new FDA cleared system is designed to improved control with a wide range of catheters. We look forward to seeing improved clot targeting, capture, maceration, and removal improve patient care.”

Control Medical’s product platform includes the Control 5 -11 French Mechanical Thrombectomy System with over-the-wire (OTW) catheters indicated for use in the peripheral vasculature and the Control RX-LP Mechanical Thrombectomy System with rapid-exchange (RX) catheters indicated for use in peripheral and coronary vasculature.

The device is distributed here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”